Free Trial

ICON Public (ICLR) Stock Price, News & Analysis

$323.46
+10.36 (+3.31%)
(As of 07/26/2024 ET)
Today's Range
$312.85
$324.69
50-Day Range
$309.52
$346.20
52-Week Range
$221.20
$347.72
Volume
908,594 shs
Average Volume
583,136 shs
Market Capitalization
$26.69 billion
P/E Ratio
39.35
Dividend Yield
N/A
Price Target
$351.33

ICON Public MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
9.0% Upside
$352.56 Price Target
Short Interest
Healthy
1.79% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.64mentions of ICON Public in the last 14 days
Based on 16 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
16.23%
From $14.54 to $16.90 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.00 out of 5 stars

Medical Sector

103rd out of 936 stocks

Commercial Physical Research Industry

4th out of 12 stocks

ICLR stock logo

About ICON Public Stock (NASDAQ:ICLR)

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.

ICLR Stock Price History

ICLR Stock News Headlines

Barclays Reaffirms Their Buy Rating on Icon (ICLR)
625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
ICON releases its ICON Cares 2023 Report
ICON Announces Pricing of USD 2 Billion Notes
See More Headlines
Receive ICLR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ICON Public and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
7/24/2024
Today
7/26/2024
Next Earnings (Estimated)
10/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Commercial physical research
Sub-Industry
Business Services
Current Symbol
NASDAQ:ICLR
Employees
41,100
Year Founded
1990

Price Target and Rating

Average Stock Price Target
$352.56
High Stock Price Target
$383.00
Low Stock Price Target
$315.00
Potential Upside/Downside
+9.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Net Income
$612.34 million
Pretax Margin
8.61%

Debt

Sales & Book Value

Annual Sales
$8.12 billion
Cash Flow
$18.85 per share
Book Value
$112.02 per share

Miscellaneous

Free Float
46,197,000
Market Cap
$26.52 billion
Optionable
Optionable
Beta
1.23

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Dr. John Climax Ph.D. (Age 71)
    Founder & Independent Non-Executive Director
    Comp: $90k
  • Mr. Brendan Brennan (Age 45)
    Chief Financial Officer
    Comp: $1.07M
  • Dr. Steven A. Cutler MBA (Age 64)
    Ph.D., CEO & Director
    Comp: $2.54M
  • Jonathan Andrew Curtain (Age 48)
    Senior Vice President of Corporate & Commercial Finance
  • Mr. Thomas N. O'Leary
    Chief Information Officer
  • Mr. Diarmaid Cunningham (Age 49)
    Chief Administrative Officer, General Counsel & Company Secretary
  • Ms. Niamh Murphy
    Director of Corporate Communications
  • Mr. David Green
    Vice President of Marketing
  • Mr. Joe Cronin
    Chief Human Resources Officer
  • Mr. Simon Holmes (Age 57)
    President of Corporate Investments & Partnerships

ICLR Stock Analysis - Frequently Asked Questions

How have ICLR shares performed this year?

ICON Public's stock was trading at $283.07 on January 1st, 2024. Since then, ICLR stock has increased by 14.3% and is now trading at $323.46.
View the best growth stocks for 2024 here
.

How were ICON Public's earnings last quarter?

ICON Public Limited (NASDAQ:ICLR) posted its earnings results on Wednesday, July, 24th. The medical research company reported $3.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.68 by $0.07. The business's revenue for the quarter was up 4.1% compared to the same quarter last year.

What is Steve Cutler's approval rating as ICON Public's CEO?

147 employees have rated ICON Public Chief Executive Officer Steve Cutler on Glassdoor.com. Steve Cutler has an approval rating of 63% among the company's employees. This puts Steve Cutler in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Does ICON Public have any subsidiaries?

ICON Public subsidiaries include these companies: PRA Health Sciences, MedPass International, MeDiNova Research, MolecularMD, Mapi Group, Clinical Research Management, PMG Research, and more.

Who are ICON Public's major shareholders?

ICON Public's top institutional shareholders include Liontrust Investment Partners LLP (0.15%), Cullen Investment Group LTD. (0.01%), Somerset Trust Co and First National Bank of Hutchinson.

How do I buy shares of ICON Public?

Shares of ICLR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of ICON Public own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ICON Public investors own include Pfizer (PFE), Gilead Sciences (GILD), Visa (V), NVIDIA (NVDA), CVS Health (CVS), UnitedHealth Group (UNH) and Alibaba Group (BABA).

This page (NASDAQ:ICLR) was last updated on 7/27/2024 by MarketBeat.com Staff

From Our Partners